TROGARZO Drug Profile

Summary for Tradename: TROGARZO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TROGARZO

Recent Clinical Trials for TROGARZO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
TaiMed Biologics Inc.	Phase 3
Westat	Phase 3

See all TROGARZO clinical trials

Pharmacology for TROGARZO

Mechanism of Action	CD4-directed Antibody Interactions HIV 1 Post-attachment Fusion Inhibitors
Established Pharmacologic Class	CD4-directed Blocking Antibody Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor
Chemical Structure	Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TROGARZO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TROGARZO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TROGARZO Derived from Patent Text Search

No patents found based on company disclosures

Trogarzo Market Dynamics and Financial Trajectory: Ibalizumab Commercial Outlook, Competition, Patents and Generic Risk

Last updated: September 8, 2026

Trogarzo, the brand name for ibalizumab-uiyk, is a niche biologic for adults with multidrug-resistant HIV-1 whose current antiretroviral regimen is failing. Its commercial profile combines a small but medically important patient population, high treatment persistence, recurring administration revenue, and limited near-term substitution risk. The principal constraints are the size of the salvage-therapy market, administration burden, payer controls, and competition from newer long-acting or oral agents such as Sunlenca and Rukobia.

Trogarzo was approved by the U.S. Food and Drug Administration in March 2018. It is marketed in North America by Theratechnologies under an agreement with TaiMed Biologics. The product generated an estimated $30 million to $35 million in annual sales in the early 2020s, making it a meaningful but secondary contributor to Theratechnologies’ revenue base, which also includes Egrifta SV.[1][2]

What is Trogarzo and who uses it?

Trogarzo is an anti-CD4 monoclonal antibody that blocks HIV-1 viral entry after the virus attaches to the CD4 receptor. It is indicated for adults with multidrug-resistant HIV-1 infection who are failing their current antiretroviral regimen.[3]

The product is not a first-line HIV treatment. Its commercial market is concentrated in heavily treatment-experienced patients who have limited remaining options because of resistance, intolerance, or prior treatment failure.

Product attribute	Trogarzo profile
Active ingredient	Ibalizumab-uiyk
Drug class	Post-attachment HIV-1 inhibitor
FDA application	BLA 761065
Initial FDA approval	March 6, 2018
Initial route	Intravenous infusion
Maintenance dosing	Every two weeks
U.S. commercial rights	Theratechnologies
Originator	TaiMed Biologics
Primary use	Multidrug-resistant HIV-1
Biosimilar status	No approved biosimilar identified
Standard exclusivity framework	12-year biologic data exclusivity from approval

Trogarzo is generally used with other active antiretroviral agents. Its effectiveness depends on constructing a background regimen with at least one or more active drugs.

How large is the Trogarzo market?

The addressable market is small relative to the overall HIV treatment market. Most people living with HIV receive combination regimens based on integrase inhibitors, nucleoside reverse transcriptase inhibitors, or other oral agents. Trogarzo is reserved for a narrow salvage population.

The commercial opportunity is defined by four factors:

1. The number of patients with multidrug-resistant HIV.
2. The rate at which those patients exhaust oral treatment options.
3. The ability of clinicians to secure reimbursement for a high-cost biologic.
4. Patient and provider willingness to manage infusion or injection visits every two weeks.

Trogarzo’s narrow label limits volume growth, but the same restriction supports pricing and persistence. Patients who respond and lack comparable alternatives may remain on therapy for extended periods.

The product’s market is therefore better characterized as a high-value, low-volume specialty market than as a broad HIV franchise.

What is Trogarzo’s financial trajectory?

Trogarzo sales have shown gradual growth rather than rapid expansion. Public filings from Theratechnologies indicate that annual Trogarzo revenue increased from the low-$20 million range after launch to approximately $30 million to $35 million in the early 2020s.[1][2]

Fiscal period	Approximate Trogarzo sales trend	Market interpretation
2018	Commercial launch year	Initial market access and physician adoption
2019	Low-$20 million range	Early uptake in salvage patients
2020	Mid-$20 million range	Recurring demand despite pandemic disruption
2021	High-$20 million range	Broader specialist adoption
2022	Around $30 million	Continued patient retention and account expansion
2023	Low-to-mid-$30 million range	Growth supported by recurring use and expanded administration options

Trogarzo’s growth rate is constrained by patient availability. Revenue expansion is more likely to come from improved diagnosis, retention, reimbursement, and switching from failing regimens than from mass-market patient acquisition.

The product also has a favorable recurring-revenue structure. Maintenance dosing occurs every two weeks, which produces a predictable treatment cycle. Revenue is less dependent on new starts than a conventional chronic oral medicine. However, the model exposes the product to treatment discontinuation, infusion-center capacity, patient adherence, and payer authorization.

For Theratechnologies, Trogarzo is strategically important but not the company’s only revenue source. Egrifta SV has historically contributed a larger share of total sales. Trogarzo therefore provides diversification within the HIV and specialty-care portfolio but does not independently support the company’s entire financial structure.

How did intramuscular administration change Trogarzo’s commercial position?

The FDA authorized intramuscular administration after the original intravenous-only label.[3][4] The change reduced administration burden for selected patients and providers.

Intravenous administration

The original regimen required administration through an infusion setting. That created several commercial barriers:

• Clinic scheduling and chair-time requirements.
• Infusion-site reimbursement complexity.
• Travel burden for patients.
• Additional nursing and pharmacy resources.
• Potential competition from oral salvage products.

Intramuscular administration

Intramuscular dosing offers a less resource-intensive option. It may expand use in outpatient settings and reduce the operational disadvantage against oral therapies.

The change does not eliminate the every-two-week treatment schedule. It also does not turn Trogarzo into a broadly convenient long-acting product comparable to six-month injectable therapies. Its benefit is incremental: lower administration friction, greater site-of-care flexibility, and improved fit for patients who remain appropriate for ibalizumab.

What drugs compete with Trogarzo?

Trogarzo competes with other therapies used in heavily treatment-experienced HIV patients. The most relevant commercial comparisons are Rukobia and Sunlenca.

Product	Active ingredient	Company	Administration	Competitive position
Trogarzo	Ibalizumab-uiyk	Theratechnologies/TaiMed	IV or IM every two weeks	Established biologic salvage option
Rukobia	Fostemsavir	ViiV Healthcare	Oral twice daily	Avoids injections and infusion sites
Sunlenca	Lenacapavir	Gilead Sciences	Long-acting injectable with oral loading regimen	Longer dosing interval and strong convenience profile
Optimized oral regimens	Multiple agents	Multiple companies	Daily oral therapy	Often used as background treatment or alternative

Trogarzo versus Rukobia

Rukobia offers oral dosing and avoids clinic administration. That is a major convenience advantage. Trogarzo may remain attractive when a patient needs a mechanism that is not dependent on the same resistance profile or when adherence to an oral regimen is problematic.

Trogarzo versus Sunlenca

Sunlenca has a materially longer dosing interval and is positioned for heavily treatment-experienced adults with multidrug-resistant HIV-1. Its administration schedule is a direct competitive challenge to Trogarzo’s two-week cycle.

Trogarzo retains several potential advantages:

• Earlier market entry.
• Established clinical experience.
• A distinct mechanism of action.
• Use in combination with active background therapy.
• Existing relationships with HIV specialists and specialty pharmacies.

Sunlenca’s longer dosing interval creates the clearest structural threat to Trogarzo’s convenience proposition.

What is the FDA exclusivity status of Trogarzo?

Trogarzo received FDA approval on March 6, 2018. As a biologic licensed under the Public Health Service Act, it benefits from 12 years of reference-product data exclusivity under Section 351(k)(7) of the statute.[5]

On that basis, the core U.S. biologic exclusivity period runs to March 6, 2030, subject to statutory interpretation, pediatric extensions, and any applicable regulatory adjustments. Data exclusivity does not necessarily determine the earliest possible biosimilar filing or launch by itself. Patent rights, regulatory review, patent litigation, and settlement agreements can alter effective market entry.

No approved biosimilar to ibalizumab-uiyk had been identified in the cited FDA materials. A biosimilar applicant would face manufacturing complexity, clinical comparability requirements, and a commercially limited target population.

What patents protect Trogarzo?

Trogarzo’s protection consists of biologic exclusivity, formulation and manufacturing know-how, antibody-related intellectual property, and any issued patents listed or otherwise asserted by the relevant rights holders.

Unlike small-molecule drugs, biologic protection is not evaluated solely through the traditional Orange Book patent framework. FDA’s Purple Book is the principal regulatory reference for licensed biologics and biosimilar relationships.[5]

Formulation and delivery protection

The intramuscular product creates additional technical and commercial protection through:

• Concentration and excipient selection.
• Stability during storage and transport.
• Syringe or vial presentation.
• Administration volume and injection tolerability.
• Manufacturing controls for a monoclonal antibody.
• Comparability between intravenous and intramuscular presentations.

These barriers may be commercially more important than a single composition-of-matter patent because a biosimilar entrant must reproduce the product’s quality attributes and demonstrate clinical similarity.

Manufacturing and know-how barriers

Manufacturing a monoclonal antibody requires validated cell culture, purification, viral clearance, formulation, fill-finish, and cold-chain processes. A competing product must also establish consistent potency and stability.

The manufacturing barrier is meaningful, but it is not permanent. Large biosimilar companies have the resources to reproduce complex biologics after sufficient commercial opportunity develops. Trogarzo’s limited patient population may reduce that incentive.

When does Trogarzo lose exclusivity?

The key statutory biologic exclusivity date is March 2030. That date does not guarantee immediate biosimilar competition.

A biosimilar competitor would need to navigate:

• 351(k) regulatory requirements.
• The Purple Book reference-product framework.
• Patent disclosures and the statutory patent-exchange process.
• Potential patent litigation.
• Manufacturing scale-up.
• Payer and specialty-pharmacy contracting.
• A relatively small commercial market.

Trogarzo could face limited effective competition before or after 2030 if a biosimilar applicant challenges relevant patents or reaches a settlement with the rights holders. No major public Paragraph IV litigation or settlement involving ibalizumab was identified in the cited public sources. Paragraph IV terminology primarily applies to abbreviated new drug applications for small-molecule products; biologic competitors generally use the 351(k) pathway.

What is the Orange Book and Purple Book status of Trogarzo?

Trogarzo is a biologic, so the Purple Book is more relevant than the Orange Book for reference-product and biosimilar information. The product’s market protection should be analyzed across four layers:

Protection layer	Relevance to Trogarzo
Biologic data exclusivity	Runs from the 2018 license date under the 12-year framework
Patent rights	May cover antibody, formulation, use, manufacture, or delivery
Regulatory complexity	351(k) applicants must establish biosimilarity
Commercial barriers	Small salvage market, specialist prescribing, and reimbursement controls

An Orange Book-style analysis alone would understate Trogarzo’s protection profile.

What patent litigation and settlement risks affect Trogarzo?

Publicly disclosed litigation has not established a major generic-entry dispute for Trogarzo comparable to the litigation histories of leading small-molecule products.

The most likely future dispute would involve a biosimilar applicant and could address:

• Antibody sequence or binding characteristics.
• Formulation and stability.
• Intramuscular administration.
• Treatment of multidrug-resistant HIV.
• Manufacturing processes.
• Patent-listing or patent-exchange obligations.

The absence of a prominent public challenge supports a low near-term litigation risk assessment. It does not remove the possibility of a later 351(k) challenge as the 2030 exclusivity date approaches.

How strong is the Trogarzo patent estate?

Trogarzo’s overall protection is moderate to strong before 2030 and more dependent on biologic exclusivity than on a visible small-molecule patent wall.

The estate has several strengths:

• A rare and clinically differentiated indication.
• Complex antibody manufacturing.
• High switching costs for patients with few alternatives.
• Recurring administration.
• No approved biosimilar.
• Regulatory exclusivity extending into 2030.

The main weaknesses are:

• A small patient population.
• Competition from longer-acting agents.
• Limited ability to expand beyond treatment-experienced HIV.
• Administration every two weeks.
• Potentially modest incentives for biosimilar developers.
• Dependence on payer authorization and specialist prescribing.

The commercial moat is stronger than the volume opportunity. Trogarzo can remain protected and profitable in a niche market without becoming a large-scale HIV product.

What generic or biosimilar launch scenarios exist?

Scenario 1: No biosimilar before 2030

This is the most favorable near-term scenario. Trogarzo continues to generate recurring revenue from established patients, with growth driven by intramuscular adoption and new salvage patients.

Scenario 2: Patent challenge near 2030

A biosimilar developer files under Section 351(k), initiates the statutory patent process, and contests selected formulation, use, or manufacturing patents. Market entry depends on litigation outcomes and settlement terms.

Scenario 3: Post-2030 biosimilar entry

A biosimilar launches after statutory exclusivity. Price erosion may be less severe than in a large autoimmune market because the patient population is small and treatment decisions are specialist-led. Payers may still impose preferred-product rules.

Scenario 4: Competitive displacement without biosimilar entry

Trogarzo loses share to Sunlenca, Rukobia, or future long-acting HIV medicines even while retaining formal exclusivity. This is the principal commercial risk before 2030.

What is the revenue exposure for Theratechnologies?

Trogarzo is material to Theratechnologies but does not represent the company’s entire revenue base. Its contribution supports recurring cash flow, commercial infrastructure, and the company’s HIV portfolio. The financial risk is concentrated in the product’s limited growth ceiling rather than an immediate patent cliff.

Revenue sensitivity is highest to:

• Patient starts and discontinuations.
• Intramuscular conversion rates.
• Reimbursement approval.
• Competitive uptake of Sunlenca.
• Net price and gross-to-net deductions.
• Specialty-pharmacy distribution.
• Manufacturing and supply continuity.

Trogarzo’s financial trajectory is likely to be characterized by stable or moderate growth followed by increasing competitive pressure as long-acting alternatives gain adoption.

Key Takeaways

• Trogarzo is a specialized biologic for multidrug-resistant HIV-1, not a broad HIV treatment.
• Its annual sales reached approximately the low-to-mid-$30 million range in the early 2020s.
• Intramuscular administration improved convenience but did not remove the two-week dosing burden.
• Sunlenca is the strongest commercial threat because of its substantially longer dosing interval.
• The principal U.S. biologic exclusivity date is March 6, 2030.
• No approved ibalizumab biosimilar or major public Paragraph IV-style challenge was identified in the cited sources.
• Trogarzo’s protection is supported by regulatory exclusivity, manufacturing complexity, specialist use, and a small commercially unattractive market for biosimilar entrants.
• The largest pre-2030 risk is competitive displacement, not conventional generic substitution.
• Theratechnologies’ exposure is meaningful but diversified through Egrifta SV and other portfolio activities.

FAQs

Is Trogarzo a long-acting HIV treatment?

Trogarzo is administered every two weeks, so it is longer-acting than daily oral therapy but substantially less extended than six-month injectable regimens such as lenacapavir-based Sunlenca.

Can Trogarzo be used alone?

No. Trogarzo is used with other antiretroviral drugs as part of an optimized background regimen.

Does Trogarzo have orphan-drug exclusivity?

Trogarzo’s key protection is its biologic reference-product exclusivity and related patent rights. The product should not be analyzed solely through an orphan-drug framework.

Which company owns Trogarzo?

TaiMed Biologics developed ibalizumab, while Theratechnologies holds commercial rights in North America under licensing arrangements.

Will a Trogarzo biosimilar automatically reduce prices after 2030?

No. A biosimilar launch would require regulatory approval, manufacturing capacity, patent resolution, and payer adoption. The small salvage population may limit the number of entrants and the scale of price competition.

References

1. Theratechnologies Inc. (2023). Annual report for the fiscal year ended November 30, 2023. Theratechnologies Inc.

2. Theratechnologies Inc. (2022). Annual report for the fiscal year ended November 30, 2022. Theratechnologies Inc.

3. U.S. Food and Drug Administration. (2018). Trogarzo (ibalizumab-uiyk) prescribing information. FDA.

4. U.S. Food and Drug Administration. (2022). FDA approves intramuscular administration of Trogarzo for multidrug-resistant HIV-1. FDA.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.